Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659127 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP19A1NOS3AKR1C3AKR1C1 | |
| SCHEMBL5660492 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP19A1NOS3AKR1C3AKR1C1 | |
| SCHEMBL2246351 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP19A1NOS3AKR1C3AKR1C1 | |
| SCHEMBL6501529 | 0.84 | HTR7 (0.46) | SMN1; SMN2CYP19A1AKR1C3AKR1C1MAOB | |
| SCHEMBL4741490 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP19A1AKR1C3AKR1C1ACHE | |
| SCHEMBL15116647 | 0.84 | ACHE (0.46) | SMN1; SMN2CYP19A1ACHESIGMAR1MAOB | |
| SCHEMBL289302 | 0.82 | AKR1C3 (0.50) | SMN1; SMN2AKR1C3AKR1C1RAB9AMAPT | |
| SCHEMBL29443025 | 0.82 | AKR1C3 (0.50) | SMN1; SMN2AKR1C3AKR1C1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL1371854 | 0.80 | AKR1C3 (0.48) | SMN1; SMN2AKR1C3AKR1C1RAB9AMAPT | |
| SCHEMBL7352959 | 0.80 | AKR1C3 (0.48) | SMN1; SMN2AKR1C3AKR1C1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-08-04 | — | — | US | claimed |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-2962992-B1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG CHEMICAL LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-2962992-B1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG CHEMICAL LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-106687446-B | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible kinase inhibitors of T790M/WT-EGFR and uses thereof | 百济神州(北京)生物科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-9923143-B2 | Fullerene derivative, organic solar cell using same, and manufacturing method thereof | LG CHEM, LTD. (KR) | 2018-03-20 | — | — | US | disclosed |
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5639902-A | FOR TREATING PSORIASIS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0611755-B1 | (Cyclohexyl)-alken compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0643057-A1 | Inhibitors of microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0611755-A1 | (Cyclohexyl)-alken compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-08-24 | — | — | EP | disclosed |
| WO-1988004292-A1 | ANTIPSYCHOTIC AMINO-POLYHYDRO-BENZ-(ISO)QUINOLINES AND INTERMEDIATES | THE UPJOHN COMPANY (US) | 1988-06-16 | — | — | WO | disclosed |
| US-4049640-A | Substituted bisnaphthylazo diphenyl ureido complement inhibitors | AMERICAN CYANAMID COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | SMN1; SMN2 3422/4885CYP19A1 137/4885NOS3 270/4885 |
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | MRPS23, MRPS22, SLC11A2 | SMN1; SMN2 740/4885CYP19A1 3468/4885NOS3 2299/4885 |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | MRPS23, MRPS22, SLC11A2 | SMN1; SMN2 724/4885CYP19A1 3464/4885NOS3 2334/4885 |
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | HEXD, CDK5, CHUK | SMN1; SMN2 3079/4885CYP19A1 1146/4885NOS3 1320/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | SMN1; SMN2 3366/4885CYP19A1 142/4885NOS3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.